Bone Sarcoma - Pipeline Review, H2 2012

Description: Bone Sarcoma – Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Bone Sarcoma - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bone Sarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Sarcoma. Bone Sarcoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bone Sarcoma.
- A review of the Bone Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bone Sarcoma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bone Sarcoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bone Sarcoma pipeline depth and focus of indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

- List of Tables 6
- List of Figures 7
- Introduction 8
- REPORT COVERAGE 8
- Bone Sarcoma Overview 9
- Therapeutics Development 10
- An Overview of Pipeline Products for Bone Sarcoma 10
- Bone Sarcoma Therapeutics under Development by Companies 12
- Bone Sarcoma Therapeutics under Investigation by Universities/Institutes 14
- Late Stage Products 18
- Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Bone Sarcoma Therapeutics – Products under Development by Companies 22
Bone Sarcoma Therapeutics – Products under Investigation by Universities/Institutes 23
Companies Involved in Bone Sarcoma Therapeutics Development 28
Genzyme Corporation 28
Amgen Inc. 29
Eli Lilly and Company 30
Merck & Co., Inc. 31
ZIOPHARM Oncology, Inc. 32
Advaxis, Inc. 33
Oncolytics Biotech Inc. 34
Simcere Pharmaceutical Group 35
Hawthorn Pharmaceuticals, Inc. 36
Jennerex Biotherapeutics, Inc. 37
PharmaMar, S.A. 38
Epeius Biotechnologies Corporation 39
Bone Sarcoma – Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Combination Products 41
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 47
cixutumumab - Drug Profile 47
ridaforolimus - Drug Profile 48
ganitumab - Drug Profile 51
JX-594 - Drug Profile 53
cereolysin - Drug Profile 54
ADXS-HER2 - Drug Profile 56
SCH-717454 - Drug Profile 57
PM-00104 - Drug Profile 58
VEGFb - Drug Profile 59
BMTP-11 - Drug Profile 60
Rexin-G - Drug Profile 61
Torisel + Doxil - Drug Profile 63
Thiotepa + Stem Cell Transplantation - Drug Profile 64
imatinib mesylate - Drug Profile 65
vincristine sulfate - Drug Profile 66
Bevacizumab + Cisplatin + Doxorubicin + Methotrexate + Ifosfamide + Etoposide - Drug Profile 67
Cyclophosphamide + Sirolimus - Drug Profile 69
proline rich polypeptide - Drug Profile 71
genetically modified T cells - Drug Profile 72
pemetrexed disodium - Drug Profile 73
Reolysin + Cisplatin + Radiation Therapy - Drug Profile 74
temsirilimus - Drug Profile 76
Bevacizumab + Vincristine + Topotecan + Cyclophosphamide - Drug Profile 77
Cisplatin + Doxorubicin + Methotrexate + Pamidronate Disodium - Drug Profile 79
Vincristine + Adriamycin + Actinomycin D + Ifosfamide - Drug Profile 81
G-CSF + Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Vincristine + Radiation Therapy - Drug Profile 82
dasatinib - Drug Profile 84
trabectedin - Drug Profile 85
Cisplatin + Doxorubicin + Etoposide + Ifosfamide + Methotrexate - Drug Profile 86
PEG-interferon Alfa-2b + Cisplatin + Doxorubicin + Methotrexate - Drug Profile 88
Busulfan + Melphalan + Thiotepa + Stem Cell Transplant - Drug Profile 89
irinotecan hydrochloride - Drug Profile 91
Aldesleukin + Tumor Cell B Lymphoblastoid Cell Line Vaccine - Drug Profile 92
Zoledronic Acid + Adriamycin + Cisplatinum + Ifosfamide - Drug Profile 93
zoledronic acid - Drug Profile 95
Vincristine + Doxorubicin + Ifosfamide + Cyclophosfamide + Etoposide + Busulfan + Melfalan + Peripheral Stem Cells Transplantation - Drug Profile 96
treosulfan - Drug Profile 98
Methotrexate + Adriamycin + Cisplatin + Ifosfamide - Drug Profile 99
Methotrexate + Adriamycin + Cisplatin - Drug Profile 100
Dactinomycin + Doxorubicin Hydrochloride + Etoposide + Ifosfamide + Vincristine Sulfate + Radiation Therapy - Drug Profile 101
Dactinomycin + Busulfan + Doxorubicin Hydrochloride + Etoposide + Ifosfamide + Melphalan + Vincristine Sulfate + Radiation Therapy + Autologous Peripheral Blood Stem Cell Transplantation - Drug Profile 103
GDC-0449 + RO4929097 - Drug Profile 105
AYRPVSRI + IFA - Drug Profile 106
AYRPVSRI + IFA + Interferon Alpha - Drug Profile 107
plerixafor - Drug Profile 108
methotrexate - Drug Profile 110
Tensirolimus + Valproic Acid - Drug Profile 111
Filgrastim + Cisplatin + Dexrazoxane + Doxorubicin + Leucovorin + Methotrexate - Drug Profile 112
Filgrastim + Cisplatin + Dexrazoxane + Doxorubicin + Leucovorin + Methotrexate - Drug Profile 114
XR9576 + Filgrastim + Docetaxel + Doxorubicin Hydrochloride + Vinorelbine Ditartrate - Drug Profile 116
XR9576 + Filgrastim + Docetaxel + Doxorubicin Hydrochloride + Vinorelbine Ditartrate - Drug Profile 118
Filgrastim SD/01 + Cyclophosphamide + Dexrazoxane + Doxorubicin + Etoposide + Ifosfamide + Vincristine Sulfate + Mesna - Drug Profile 119
Filgrastim + Isopetaxetrone + Peripheral Blood Stem Cell Transplantation + Samarium Sm 153 Lexidronam Pentasodium - Drug Profile 120
Filgrastim + Ifosfamide + Peripheral Blood Stem Cell Transplantation + Samarium Sm 153 Lexidronam Pentasodium - Drug Profile 122
Trimetrexate + Leucovorin - Drug Profile 124
Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Vincristine + Radiation Therapy - Drug Profile 125
Pazopanib hydrochloride - Drug Profile 127
Therapeutic Autologous Dendritic Cells + Indinavir Sulfate + Stem Cell Transplantation - Drug Profile 128
CCI-779 + IMC-A12 - Drug Profile 130
Methotrexate + Cisplatin + Doxorubicine - Drug Profile 132
busulfan - Drug Profile 134
Cisplatin + Doxorubicin + Methotrexate - Drug Profile 135
Adriamycin + Cisplatinum + Ifosfamide - Drug Profile 137
Filgrastim SD/01 + Cyclophosphamide + Dexrazoxane + Doxorubicin + Etoposide + Ifosfamide + Vincristine Sulfate + Mesna - Drug Profile 139
Docetaxel + Gemcitabine + Filgrastim + Pegfilgrastim - Drug Profile 142
trabectedin - Drug Profile 143
sargramostim - Drug Profile 144
cixutumumab - Drug Profile 145
treosulfan - Drug Profile 147
zoledronic acid - Drug Profile 148
everolimus - Drug Profile 149
haw mAb-11 - Drug Profile 150
Sirolimus + Celecoxib + Etoposide + Cyclophosphamide - Drug Profile 151
RO4929097 + Dexamethasone - Drug Profile 152
Palifosfamide + etoposide + carboplatin - Drug Profile 153
Endostar + Methotrexate + Cisplatin + Pirarubicin + Ifosfamide - Drug Profile 154
Dexrazoxane + Doxorubicin + Methotrexate + Ifosfamide + Etoposide - Drug Profile 156
Cytosan + Doxorubicin + Vincristine + Irinotecan + Temozolomide + Neulasta + Mesnex - Drug Profile 158
Etoposide + Carboplatin + Cyclophosphamide + Mesna + Melphalan + Tandem Peripheral Blood Stem Cell - Drug Profile 160
Vincristine + Cyclophosphamide + Adriamycin + Etoposide + Cisplatin + Carboplatin + Melphalan + Ifosfamide + Granulocyte-Colony Stimulating Factor + Mesna - Drug Profile 162
Vincristine + Topotecan + Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide - Drug Profile 164
Vincristine + Doxorubicin + Cyclophosphamide + Dexrazoxane + ImmTher + Mesna + Neupogen + Neulasta - Drug Profile 166
EF-2 Peptide + IL-2 + Autologous T-Cell Transplantation - Drug Profile 168
EF-2 Peptide + IL-2 - Drug Profile 170
PXFK Peptide + IL-2 - Drug Profile 171
PXFK Peptide + IL-2 + Autologous T cell Transplantation - Drug Profile 172
E7 Peptide + IL-2 - Drug Profile 174
E7 Peptide + IL-2 + Autologous T Cell Transplantation - Drug Profile 176
Thalidomide - Drug Profile 178
List of Tables
Number of Products Under Development for Bone Sarcoma, H2 2012 16
Products under Development for Bone Sarcoma – Comparative Analysis, H2 2012 17
Number of Products under Development by Companies, H2 2012 19
Number of Products under Investigation by Universities/Institutes, H2 2012 21
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 22
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 23
Comparative Analysis by Late Stage Development, H2 2012 24
Comparative Analysis by Mid Clinical Stage Development, H2 2012 25
Comparative Analysis by Early Clinical Stage Development, H2 2012 26
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 27
Products under Development by Companies, H2 2012 28
Products under Investigation by Universities/Institutes, H2 2012 29
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 30
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 31
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 32
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 33
Genzyme Corporation, H2 2012 34
Amgen Inc., H2 2012 35
Eli Lilly and Company, H2 2012 36
Merck & Co., Inc., H2 2012 37
ZIOPHARM Oncology, Inc., H2 2012 38
Advaxis, Inc., H2 2012 39
Oncolytics Biotech Inc., H2 2012 40
Simcere Pharmaceutical Group, H2 2012 41
Hawthorn Pharmaceuticals, Inc., H2 2012 42
Jennerex Biotherapeutics, Inc., H2 2012 43
PharmaMar, S.A., H2 2012 44
Epeius Biotechnologies Corporation, H2 2012 45
Assessment by Monotherapy Products, H2 2012 46
Assessment by Combination Products, H2 2012 47
Assessment by Stage and Route of Administration, H2 2012 49
Assessment by Stage and Molecule Type, H2 2012 52
Bone Sarcoma Therapeutics – Drug Profile Updates 185
Bone Sarcoma Therapeutics – Discontinued Products 199
Bone Sarcoma Therapeutics – Dormant Products 200
Bone Sarcoma Therapeutics – Dormant Products (Contd..1) 201
Bone Sarcoma Therapeutics – Dormant Products (Contd..2) 202
Bone Sarcoma Therapeutics – Dormant Products (Contd..3) 203
Bone Sarcoma Therapeutics – Dormant Products (Contd..4) 204
Bone Sarcoma Therapeutics – Dormant Products (Contd..5) 205

List of Figures
Number of Products under Development for Bone Sarcoma, H2 2012 16
Products under Development for Bone Sarcoma – Comparative Analysis, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 20
Late Stage Products, H2 2012 24
Mid Clinical Stage Products, H2 2012 25
Early Clinical Stage Products, H2 2012 26
Discovery and Pre-Clinical Stage Products, H2 2012 27
Assessment by Monotherapy Products, H2 2012 46
Assessment by Combination Products, H2 2012 47
Assessment by Route of Administration, H2 2012 48
Assessment by Stage and Route of Administration, H2 2012 49
Assessment by Molecule Type, H2 2012 50
Assessment by Stage and Molecule Type, H2 2012 51

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2245180/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Bone Sarcoma - Pipeline Review, H2 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/2245180/">http://www.researchandmarkets.com/reports/2245180/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCD2I6NT</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
</tr>
<tr>
<td>Single User:</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
</tr>
<tr>
<td>Site License:</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
</tr>
<tr>
<td>Enterprisewide:</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr [] Mrs [] Dr [] Miss [] Ms [] Prof []</td>
</tr>
<tr>
<td>First Name:</td>
</tr>
</tbody>
</table>
| _______________________
| Last Name:             |
| _______________________
| Email Address: *       |
| _______________________
| Job Title:             |
| _______________________
| Organisation:          |
| _______________________
| Address:               |
| _______________________
| City:                  |
| _______________________
| Postal / Zip Code:     |
| _______________________
| Country:               |
| _______________________
| Phone Number:          |
| _______________________
| Fax Number:            |
| _______________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card:
  You will receive an email with a link to a secure webpage to enter your credit card details.

- Pay by check:
  Please post the check, accompanied by this form, to:
  Research and Markets,
  Guinness Center,
  Taylors Lane,
  Dublin 8,
  Ireland.

- Pay by wire transfer:
  Please transfer funds to:
  Account number 833 130 83
  Sort code 98-53-30
  Swift code ULSBIE2D
  IBAN number IE78ULSB98533083313083
  Bank Address Ulster Bank,
    27-35 Main Street,
    Blackrock,
    Co. Dublin,
    Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World